Key facts
- Lyfegen’s last known valuation is $33.9M (Dec 2024).
- It has raised $17.1M; the latest was Later Stage VC ($5.7M) in Dec 2024.
- Notable investors include Plug and Play Tech Center, MassChallenge, APEX Ventures, Startup Creasphere, SwissHealth Ventures — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Lyfegen
- ·The full record, as it builds
Funding rounds
No funding rounds for Lyfegen are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Lyfegen
Developer of an independent provider of rebate management software designed for the healthcare industry. The company offers solutions for the healthcare industry to identify the right drug pricing agreements, simulate and understand the financial impacts of those agreements, and automate the execution and adjudication of them-thus delivering a measurable reduction in administrative effort in rebate management and optimization, enabling clients to improve access to treatments, patient health outcomes, and affordability.
- Sector
- Healthcare
- HQ
- Basel, Switzerland
- Founded
- 2018
- Employees
- 50
- Website
- lyfegen.com/
- Ownership
- Privately Held (backing)
Lyfegen doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Lyfegen shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Lyfegen in its N-PORT filings yet. We sweep new filings monthly.